The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jpca.4c08558.

The company is preparing for key milestones, including the submission of a Phase 2b clinical trial investigational new drug application in the second half of 2025 and a Breakthrough Therapy ...